Influence of 4‐week or 12‐week glucocorticoid treatment on metabolic changes in patients with active moderate‐to‐severe thyroid‐associated ophthalmopathy

• Main Authors: Xiaoman Chen (Author), Buatikamu Abudukerimu (Author), Qin Li (Author), Qing Li (Author), Jie Qiao (Author), Dongping Lin (Author), Chunhua Sui (Author), Lin Ye (Author), Hualing Zhai (Author), Boren Jiang (Author), Ningjian Wang (Author), Mengda Jiang (Author), Xiaofeng Tao (Author), Ziyang Shao (Author), Chenfang Zhu (Author), Yubo Ma (Author), Ping Xiong (Author), Jing Sun (Author), Huifang Zhou (Author), Bing Han (Author), Yingli Lu (Author)
• Format: Book
• Published: Wiley, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Thyroid‐associated ophthalmopathy (TAO) is a serious, progressive, vision‐threatening and difficult‐to‐treat organ‐specific autoimmune disease. The course, therapeutic effects and prognosis of moderate to severe TAO vary greatly. High‐dose intravenous glucocorticoid (IVGC) therapy is consid...